AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05799846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMOTE Behavioral Weight Loss Intervention
Description: 12-month online behavioral weight loss intervention focused on promoting future benefits of maintaining a healthy weight
Study NCT04971499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: 500 mg tablet
Study NCT04971499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Single-use vial containing 100 mg/4 mL of pembrolizumab
Study NCT05545475 — intervention group
Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Anticoagulants were given. When using warfarin, international normalized ratio (INR) was detected every 3-4 days and adjusted carefully by 0.75mg dosage until achieve the target level of 2-3.
Study NCT05137236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283
Description: Sterile liquid for injection
Study NCT05137236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.211
Description: Sterile liquid for injection
Study NCT05137236 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273
Description: Sterile liquid for injection
Study NCT05137236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1283.529
Description: Sterile liquid for injection
Study NCT05862935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity (AMRAP -As Many Repetitions As Possible): Phase 2
Description: 20-30 min/session, 3 times/week for 4 weeks. After a 5-min warm-up, participants perform a moderate-intensity functional training program. This program is designed in circuit mode consisting of 6 global functional exercises: i) sit and stand, ii) forward lunges, iii) chest press, iv) high row, v) lateral shoulder raises and vi) heel raises. Participants must complete the highest number of repetitions and/or rounds as possible (AMRAP) in 15-min without a designated rest.
Study NCT05862935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Physical Activity: Phase 1
Description: 40-60 min/session, 3 times/week for 12 weeks. After a 5-min warm-up, participants performed 6 global functional exercises: i) sit-to-stand; ii) chest press, iii) forward lunges; iv) unilateral shoulder raises; v) unilateral row; and vi) heel raises. The initial volume is 2 sets and 8 repetitions and it will progressively increase until 3 sets and 12 repetitions.
Study NCT05316558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Confident Coaching
Description: The Body Confident Coaching program is a five-module online program aimed at upskilling coaches in identifying and tackling body image concerns among girls in sport. Each module will take approximately 20 minutes to complete and consists of educational content, interactive elements (quizzes, checklists, opinion polls, reflective exercises), and additional resources.
Study NCT05976789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound therapy using low-level background sound
Description: This study will use an FDA-regulated device, a tinnitus masker, as one of the sound therapy options in Aim 2.~The tinnitus masker will provide low-level background sound for hyperacusis relief.
Study NCT05976789 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote counseling using HAT-Online
Description: This study will implement Hyperacusis Activities Treatment-Online, a four-week remote counseling program in Aim 1.
Study NCT05976789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sound therapy using successive approximations
Description: This study will use the approach of successive approximations with the participants' bothersome sounds in Aim 2.
Study NCT05810701 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive geriatric assessment and individualised physical training
Description: Comprehensive geriatric assessment and relevant intervention (including medical and pharmacological optimisation, nutritional, social and psychological intervention, among others), and individualised physical training
Study NCT05281406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg daily or reduced dose 40 mg daily
Study NCT05281406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study NCT04885855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400 MG
Description: Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
Study NCT04885855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 MG
Description: Sofosbuvir is a direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5B (NS5B)
Study NCT04885855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ravidasvir 200mg
Description: Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
Study NCT04885855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir 200mg
Description: Ravidasvir is an investigational direct-acting antiviral (DAA) a nucleotide analog inhibitor of hepatitis C virus nonstructural protein 5A (NS5A)
Study NCT06274229 — intervention group
Intervention type: OTHER
Intervention: Air pollution and noise reducing installations
Description: A number of means to reduce traffic noise and traffic exhausts and improve air quality will be implemented at designated urban spaces (intervention sites), while other places with comparable amount of traffic and no such changes will serve as control sites.
Study NCT05281406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study NCT05281406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 mg/mL/min i.v. d1 of every 21-day cycle for a maximum of 4 cycles
Study NCT06226272 — intervention group
Intervention type: DEVICE
Intervention: Spinal Fusion
Description: Cervical Spinal Fusion
Study NCT06226272 — intervention group
Intervention type: DEVICE
Intervention: Spinal Fusion
Description: Thoracic / Lumbar Spinal Fusion
Study NCT06226272 — intervention group
Intervention type: DEVICE
Intervention: Spinal Deformities Correction
Description: Spinal Deformities Correction
Study NCT05789329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Informed Guilt Reduction Therapy
Description: behavioral intervention aimed to reduce trauma-related guilt and shame
Study NCT05789329 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: behavioral intervention aimed at reducing PTSD symptoms
Study NCT04664205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Exercise
Description: One session of high intensity interval exercise
Study NCT04664205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise
Description: One session of calorically matched moderate intensity exercise
Study NCT04664205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No exercise, resting measures
Study NCT05312996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heart Rate Variability
Description: Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
Study NCT05312996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability
Description: Caretaker Heart Rate Variability ECG wrist monitor and chest patch.
Study NCT05312996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Galvanic Skin Response (Biopac)
Description: Galvanic Skin Response- measuring autonomic response-via perspiration
Study NCT05312996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Galvanic Skin Response (Biopac)
Description: Galvanic Skin Response- measuring autonomic response-via perspiration
Study NCT04886726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uhCG/EGF
Description: PTCY for 2 doses on day +3 and +4 after stem cell transplant followed by uhCG/EGF subcutaneously on day +7, +9 and +11 post stem cell transplant
Study NCT06312917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Exercise intervention According to the guidelines of the American Sports Medicine Association (ACSM) and the National Fitness guidelines of the General Administration of Sport of China, the FITT-VP principle of ACSM is adopted. The patients were given the intervention guidance of aerobic exercise, resistance training and flexibility training. During the training, the patients filled in the weekly training records, including the feeling after each training, physical dimension and other relevant information, and the nurses gave personalized exercise guidance according to the patients' conditions.The diet is to maintain a balanced diet.
Study NCT05564572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Health Status Assessment
Description: Completion of a patient-reported health status assessment preceding each clinic visit. The health status assessment consists of the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) along with additional select questions. The results of the assessment will be available to clinicians in the electronic health record.
Study NCT06148870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia Control Lens-1 (MCL1)
Description: The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
Study NCT06148870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia Control Lens-1 (MCL1)
Description: The MCL1, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on one eye for 6 months.
Study NCT06148870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myopia Control Lens-2 (MCL2)
Description: The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
Study NCT06148870 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myopia Control Lens-2 (MCL2)
Description: The MCL2, is a myopia control lens that corrects refractive error and simultaneously creates myopia control signals. It will be worn on the contralateral eye for 6 months.
Study NCT03939104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine+amodiaquine
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~AQ: Amodiaquine is available as dispersible tablets of 40 mg. The weight-based treatment schedule aims for a dosage of approximately 10mg (4.5-15mg)/kg/day amodiaquine for three days.
Study NCT03939104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine+placebo
Description: AL: Currently available as dispersible tablets containing 20 mg of artemether and 120 mg of lumefantrine, in a fixed-dose combination formulation. The flavoured dispersible tablet paediatric formulation facilitates use in young children.~The dose of artemether-lumefantrine is administered approaching the WHO-recommended target ranges of artemether 5-24 mg/kg and lumefantrine 29-144 mg/kg over 3 days.~PBO: Placebo tablets for amodiaquine are identical in size, shape and color to the amodiaquine tablets.
Study NCT06460753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT of the chest organs, blood biochemical parameters
Description: Taking into account the clinical manifestations, all patients underwent chest computed tomography (CT) to diagnose COVID-19-associated pneumonia. According to the CT results, all patients were classified into one of 4 subgroups, according to the degree of pulmonary infiltration. The following biochemical parameters were selected and used to monitor dynamics: procalcitonin (PCT), C-reactive protein (CRP), D-dimer (DD), ferritin (FRT). Biochemical markers were determined daily during the stay in the intensive care unit. The duration of observation was 15 days was selected. Information was analysed retrospectively.
Study NCT03939104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine+piperaquine
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PPQ: Piperaquine will be administered according to an optimised dosing schedule using tablets of 160 or 500 mg of piperaquine tetraphosphate. The weight-based treatment aims for a dosage of approximately~* 24 mg/kg/day in patients \<25 kg (range 16.0 - 32.0 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 20 - 32 mg/kg per day.~* 18 mg/kg/day in patients ≥25 kg (range 15.0 - 29.4 mg/kg) piperaquine for three days, thereby approaching the WHO-recommended target range of 16 - 27 mg/kg per day.
Study NCT03939104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-mefloquine+placebo
Description: AS: Artesunate will be administered according to an optimised dosing schedule using tablets of 32 or 100 mg artesunate with a dosing target of 4 mg/kg/day.~MQ: Mefloquine will be administered according to an optimised dosing schedule using tablets of 70 or 220 mg mefloquine hydrochloride with a dosing target of 8.3 mg/kg/day.~PBO: Placebo tablets for piperaquine are identical in size, shape and colour to the piperaquine tablets.
Study NCT05093582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levcromakalim
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
Study NCT05093582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 12 active episodic patients, 15 episodic patients in remission and 20 chronic patients of both genders are randomized to receive a 20-minute infusion of levcromakalim and/or sterile saline on two days, with at least 3 days in between.
Study NCT05413798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine HPV testing
Description: Human papillomavirus (HPV) testing in urine sample.
Study NCT05413798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-collected cervicovaginal specimen
Description: Human papillomavirus (HPV) testing in self-collected cervicovaginal specimen sample.
Study NCT05413798 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Provider-collected cervical samples
Description: Human papillomavirus (HPV) testing in healthcare provider collected cervicovaginal specimen sample.
Study NCT06088693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and Standard Therapy
Description: Acupuncture Needle Insertion with Electroacupuncture machine.
Study NCT05735704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for HemaChip screening/diagnostic testing
Description: Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.
Study NCT05735704 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow sampling
Description: as part of the discovery stage, bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure. Additionally, up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery.
Study NCT05584098 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: qSOFA and MEWS
Description: qSOFA and MEWS used in emergency medicine department could be helpful in the identification of the occurrence of sepsis
Study NCT05010278 — intervention group
Intervention type: PROCEDURE
Intervention: Latarjet
Description: Patients followed up 6 months after a Latarjet procedure
Study NCT06069804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The TR group
Description: Miscible liquid of triamcinolone acetonide and ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, 0.25ml triamcinolone acetonide (40mg/ml), plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Study NCT06069804 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The R group
Description: Miscible liquid of ropivacaine in this study will be peri-incisional scalp infiltration with 10ml ropivacaine 1% wt/vol, plus 10 ml saline miscible liquids for participants who will undergo elective craniotomy. Local infiltration of the study solution was performed by the neurosurgeon after induction of general anesthesia and intubation, once all equipment and catheters had been placed, during stable and steady state anesthetic conditions before skin incision. The solution was infiltrated with a 22-gauge needle introduced into the skin at a 45° angle throughout the entire thickness of the scalp along the planned incision site and the head-holder sites, by the same neurosurgeon. The total volume of the study solution used for each patient was determined by the neurosurgeon mainly based on the length of the incision and recorded by the investigator.
Study NCT06196827 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LX101
Description: Subretinal Administration
Study NCT06545305 — intervention group
Intervention type: PROCEDURE
Intervention: Lensectomy and vitrectomy
Description: Corrections
Study NCT05812950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GST
Description: Outpatient eating disorder treatment (5 individual pre-group sessions followed by 26 weekly group sessions + 8 optional individual sessions)
Study NCT05812950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: Outpatient eating disorder treatment (20-40 weekly individual sessions)
Study NCT05570097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intercostal nerves cryoanalgesia
Description: Intraoperative Cryolesia of at least 5 intercostal nerves added to regional analgesia: bilateral erector spine plane block and multimodal therapy.
Study NCT05599659 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative care
Description: It is a pilot model of outpatient clinical care for patients in advanced stages of PDRD that will allow earlier access to PC in this population. PC visits will be in person or by telemedicine every three months and complemented with phone calls by different team members when needed as defined by the PC team.~The typical visit duration will be 2 to 2.5 hours and address nonmotor symptoms, goals of care, anticipatory guidance, difficult emotions, and carepartner support. Providers will communicate in-person or via notes during the clinic visit to increase interdisciplinary coordination and meet at the end of the day for discussion including follow-up plans.~The team will consist of a neurologist, a registered nurse with palliative care experience and training, a psychology counselor, a social worker, spiritual counselor and a research assistant.
Study NCT04229043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sports drink
Description: Drink that will be ingested
Study NCT04229043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Drink that will be ingested
Study NCT05911217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT041 autologous CAR T-cell injection
Description: Treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion. Up to 3 times CT041 autologous CAR T-cell injection infusion